CatalystMarker
← board

TRAX

distress 3/10 · well-funded / low risk
$37.01-3%today-3% from 52w high
firsttracksbio.com104 employeesFounded 2019San Diego, CABiotechnology
Revenue
pre-revenue
Liquidity
$248M
Runway
1.9 yrs
Shares 1y

Price & events

+94.8% over 6M
$15.32$26.74$38.17Apr 26May 26Jul 264.5Mdilution: 424B3 offering (2026-05-15)dilution: 424B3 offering (2026-05-14)dilution: EFFECT shelf_effective (2026-05-12)dilution: S-1 shelf_registration (2026-05-08)financing: 8-K material_agreement (2026-06-22)financing: 8-K private_placement (2026-04-20)
CatalystRating changeDilutionFinancingdashed = today
-3.0%
1D
+2.2%
1W
+108.2%
1M
+94.8%
3M
6M
1Y
2Y
5Y
+94.8%
All

Overview

Market Cap
$1.29B
Volume
22.03K
52 Week Range
$15.32 – $38.17
Total Shares
34.89M
Float Shares
31.05M
% Held by Insiders
6.60%
% Held by Institutions
50.79%
RVOL
0.03x

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 34,892,381 · 2 offerings/1y · 1 PIPEs
  • 2026-06-228-Kmaterial_agreement
  • 2026-05-15424B3offering
  • 2026-05-14424B3offering
  • 2026-05-12EFFECTshelf_effective
  • 2026-05-08S-1shelf_registration
  • 2026-04-208-Kprivate_placement
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

strong buy · target $43 (+16% upside) · 8 analysts
  • no recent rating changes

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.